Physician profile
Daniel A Schwartz
NPI 1609913391
$16,799.97
in general payments reported to CMS, 2019-2025
41 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,515 · 2020: $3,194 · 2021: $5,500 · 2022: $3,650 · 2023: $150 · 2024: $983 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $2,914.63 | 2019-2022 | |
| Novo Nordisk INC | $1,262.71 | 2019-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $1,108.38 | 2019-2022 | |
| Abbvie INC. | $1,083.74 | 2020-2025 | |
| Lilly USA, LLC | $1,054.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $971.62 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $887.28 | 2019-2024 | Arexvy |
| Abbott Laboratories | $753.17 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $737.42 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $582.78 | 2019-2022 | |
| Gilead Sciences, INC. | $525.60 | 2019-2022 | |
| Astellas Pharma US INC | $499.29 | 2019-2025 | Veozah, Izervay |
| Teva Pharmaceuticals USA, INC. | $489.65 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $470.74 | 2019-2022 | |
| Pfizer INC. | $464.49 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.